SCHEMBL15035217

SCHEMBL15035217

CCn1c(=O)c(-c2ccc(-c3ccccc3C)cc2Cl)cc2cnc(Nc3ccc(C4=CCNCC4)cc3)nc21

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PAK1 Q13153 6/20 0.53
PKN1 Q16512 4/20 0.53
PAK4 O96013 3/20 0.53
PAK2 Q13177 5/20 0.53
PAK3 O75914 3/20 0.53
LIMK1 P53667 1/20 0.53
LIMK2 P53671 1/20 0.53
FGFR1 P11362 3/20 0.53
EGFR P00533 2/20 0.53
WEE1 P30291 1/20 0.48
STK4 Q13043 4/20 0.48
STK3 Q13188 4/20 0.48
SIK2 Q9H0K1 4/20 0.48
STK26 Q9P289 4/20 0.48
STK24 Q9Y6E0 4/20 0.48
TNK2 Q07912 1/20 0.46
RIPK2 O43353 1/20 0.45
ACVR1 Q04771 1/20 0.45
NOD2 Q9HC29 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035218 0.92 PAK1 (0.58) PAK1PKN1PAK4PAK2PAK3
SCHEMBL14824730 0.91 PAK1 (0.53) PAK1PKN1PAK4PAK2PAK3
SCHEMBL13554101 0.90 PKN1 (0.56) PAK1PKN1PAK4PAK2PAK3
SCHEMBL14824731 0.89 PAK1 (0.55) PAK1PKN1PAK4PAK2PAK3
SCHEMBL13554089 0.89 PAK1 (0.52) PAK1PKN1PAK4PAK2PAK3
SCHEMBL13554087 0.88 PAK1 (0.55) PAK1PKN1PAK4PAK2PAK3
SCHEMBL12807729 0.88 PAK1 (0.56) PAK1PKN1PAK4PAK2PAK3
SCHEMBL15035136 0.88 PAK1 (0.58) PAK1PKN1PAK4PAK2PAK3
SCHEMBL14824725 0.87 PAK1 (0.57) PAK1PKN1PAK4PAK2PAK3
SCHEMBL14824722 0.86 PKN1 (0.71) PAK1PKN1PAK4PAK2PAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 PAK1 4/4885PKN1 326/4885PAK4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.